TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Clinical Global Impression - Improvement Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ordinal Scale of Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cleanliness of the bowel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Average number of periodic leg movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Wound Surface Area Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: True Negative Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Weight<10th Percentile for Age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Length <10th Percentile for Age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Head Circumference <10th Percentile for Age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Development Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of positive TB cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in the cortical directed connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in the graph theory indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Seropositive Subjects for H1N1 Haemagglutination Inhibition (HI) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Titers for H1N1 Haemagglutination Inhibition (HI) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroconverted Subjects in Terms of H1N1 Haemagglutination Inhibition (HI) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cognitive profile evaluation measured by MMSE score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Quality of life measured by EQ-5D
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Respiratory Distress Assessment Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of participants accurately assessed by CADe tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amelioration of phenotypic features of autism
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Functional Health Literacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Individualized Care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Maximum tolerated dose (MTD) of buparlisib with ibrutinib
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Maximum tolerated dose (MTD) of buparlisib with ofatumumab
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Incidence of Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percent correct pattern identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance of QTF-GIT test and TST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Positivity of QTF-GIT in comparison with TST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Negative QTF-GIT test in comparison with TST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: maximum tolerated-dose (MTD) of RAD001
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose of Vorinostat
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Survival at 15 Months
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative incidence of virological failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Administration of Benralizumab 30 mg SC by Injection
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Returned APFS Evaluated as Functional
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: APFS Reported as Malfunctioning
Endpoint domain: Adverse events/effects
Primary endpoint: Syphilis diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Chlamydia diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Gonorrhea diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in constant score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: platelet function parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: coagulation parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Difference in correct locations of the BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Patients' Control Preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of Patients' Decision Self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Global end diastolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change Left ventricular volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change Right ventricular volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Return to baseline SHIM score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Frailty and functional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum myokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight Loss of ≥15% From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean DAS28 Post Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of Patients Experiencing at Least One Adverse Event (AE) of Special Interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the concentration-time curve of midazolam (AUC0-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration of midazolam in plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Total Testosterone Level - Maximum Observed Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Blood glucose response curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: central venous oxygen saturation (ScvO2) variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of lung disease after HSCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AUC of the late asthmatic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy of PPI therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Viral Load blood level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Preferences for autonomy
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Changing of the lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence and incidence of smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical malaria incidence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Fatty Liver Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Insulin Resistance (HOMA-IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Substance Use Problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risky Behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Academic Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Plantar forces under the hallux and the forefoot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to OZURDEX® Re-injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Productivity of agricultural workers
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Safety of ATG003
Endpoint domain: Adverse events/effects
Primary endpoint: Pain syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative ventral hernia
Endpoint domain: Adverse events/effects
Primary endpoint: Defects in the aponeurosis
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time from discontinuation of anesthesia to extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Innate Cell IFNa2a Production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hemagglutination Inhibition Ab Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Memory B Cell ELISPOT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to expel kidney stone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Steady state PF 04447943 Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady state Donepezil Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COVID-19 Detection Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: regional brain responses during visceral pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient's interest in care proposal
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Birchwood Social Function Scale (BSFS) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Total body, hip and lumbar spine bone mass deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Nicotine level on finger #1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nicotine level on finger #2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nicotine level on finger #3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With IMP-Related Predefined Safety Criteria Findings
Endpoint domain: Adverse events/effects
Primary endpoint: Delta between Glucose Infusion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Apnoea-Hypopnea Index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Neuron-specific serum enolase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSF glutamate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSF S100B levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Imaging efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-Free Survival (DFS) - Number of Events
Endpoint domain: Mortality/survival
Primary endpoint: Disease-Free Survival (DFS) - Time to Event
Endpoint domain: Mortality/survival
Primary endpoint: ARFI velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of gestational diabetes mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time-Weighted Average Change From Baseline in DAS28-CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-Weighted Average Change From Baseline in Patient Global Assessment of Pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prolongation of the survival curve
Endpoint domain: Mortality/survival
Primary endpoint: Confirmed Clearance of Plasma Cytomegalovirus (CMV) DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Renal medullary perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: changes in assessment of shoulder, abdominal and incisional pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of DNA vaccine injections
Endpoint domain: Adverse events/effects
Primary endpoint: Use of catecholamines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fiber density of the subbasal nerves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Accuracy of IEM Detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Latency Period of Signal Detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Methylation pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Autism Treatment Evaluation Checklist (ATEC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Clinical Impression (GCI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adverse event reported
Endpoint domain: Adverse events/effects
Primary endpoint: MLHFQ Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: PAH-SYMPACT Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Score on a psychomotor development scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cortisol serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Endothelial function measured by RHI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy in displaying the superficial temporal artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech and language assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Upper arm vein diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ADHD-RS-IV score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of ex-vivo imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative shoulder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital Stay in days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: model-derived parameters of neurovascular coupling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Irritable Bowel Syndrome Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of Treatment-Emergent Laboratory Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: clinical effectiveness of EUS-guided CB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of avian influenza (AI) in poultry-exposed populations
Endpoint domain: Mortality/survival
Primary endpoint: Sero-prevalence rates of infection with AI viruses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of retinal vessels crossing the optic disc
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum level of endostatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of intervention for bradycardia
Endpoint domain: Adverse events/effects
Primary endpoint: Success rate of first line therapy for Helicobacter pylori infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Success rate of second line therapy for Helicobacter pylori infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Plasma concentration of [14C]-BGB-3111 as measured by area under concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of [14C]-BGB-3111
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time To Maximum Plasma Concentration (Tmax) of [14C]-BGB-3111
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electromyographic activity of respiratory muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Volume variation of thoracoabdominal wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants Who Received All Needed Screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Who Received Any Needed Screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in the Frequency of RBD
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change From Baseline in WOMAC Pain Subscale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in WOMAC Physical Function Subscale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Patient's Global Assessment of Osteoarthritis Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety and tolerability of ANG1005
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of ANG1005
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability, in terms of incidence of graft-versus-host disease and local/systemic toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Response at the Test of Cure (TOC) Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: de-novo occurrence of intra-cerebral lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Modified PASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of participants experiencing eribulin-induced peripheral neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants experiencing eribulin-induced peripheral neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Time to eribulin treatment discontinuation due to eribulin-induced peripheral neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Colonic Transit, Colonic Geometric Center at 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change Between Postprandial and Fasting Whole Gastric Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Half Time (t1/2) of Gastric Emptying of Solids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Major pathologic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Dispatcher recognition of cardiac arrest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Optic nerve sheath diameter (ONSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed diagnosis of food allergy at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Survival at 30-days
Endpoint domain: Mortality/survival
Primary endpoint: absolute tissue saturation (StO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall response (OR) in metastatic clear cell renal cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall response (OR) in metastatic Papillary cell renal cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall response (OR) in metastatic renal cell cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Accuracy of Nasosorption for Viral Load Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Bronchosorption for Viral Load Measurement, Compared to Tracheal Aspirate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes